Chief Medical Officer · CRESCENT BIOPHARMA, INC. (CBIO)

Ellie Im

FY2025 is the first fiscal year CompBrief holds for Ellie Im as a named executive officer of CRESCENT BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$3,662,495

Compensation figures as of the proxy filed April 21, 2026 (DEF 14A).

Ellie Im compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$401,250
Stock awards$281,347
Option awards$2,666,923
Non-equity incentive$312,975
Total$3,662,495

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 21, 2026, accession 0001628280-26-026282, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU21,298$252,594—
Option65,190—$13.21

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

CRESCENT BIOPHARMA’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Joshua BrummChief Executive Officer & Director$13,116,834
Jonathan McNeillChief Operating Officer & President$6,604,328
Ellie Im · this pageChief Medical Officer$3,662,495

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CRESCENT BIOPHARMA's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy